Iovance Biotherapeutics, Inc. IOVA Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease right-of-use assets in other assets of $44.38M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets decreased by 12.8% year-over-year, from $50.9M to $44.38M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease right-of-use assets in other assets has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.